tradingkey.logo

Pharming Group NV

PHAR

11.720USD

+0.760+6.93%
Market hours ETQuotes delayed by 15 min
0.00Market Cap
--P/E TTM

Pharming Group NV

11.720

+0.760+6.93%
More Details of Pharming Group NV Company
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
Company Info
Ticker SymbolPHAR
Company namePharming Group NV
IPO dateJul 02, 1998
CEODr. Sijmen (Sijmen) De Vries, M.D.
Number of employees- -
Security typeOrdinary Share
Fiscal year-end- -
AddressDarwinweg 24
CityLEIDEN
Stock exchangeLondon Stock Exchange
CountryNetherlands
Postal code2333 CR
Phone31715247400
Websitehttps://www.pharming.com/
Ticker SymbolPHAR
IPO dateJul 02, 1998
CEODr. Sijmen (Sijmen) De Vries, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Jeroen Wakkerman
Mr. Jeroen Wakkerman
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Fabrice Chouraqui
Mr. Fabrice Chouraqui
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Stephen Toor
Mr. Stephen Toor
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Alexander Breidenbach
Dr. Alexander Breidenbach
Chief Business Officer
Chief Business Officer
--
--
Ms. Ines Bernal
Ms. Ines Bernal
Chief People Officer
Chief People Officer
--
--
Mr. Steven Baert
Mr. Steven Baert
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Jabine Van Der Meijs
Ms. Jabine Van Der Meijs
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Leonard Kruimer, CPA
Mr. Leonard Kruimer, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Anurag Relan, M.D.
Dr. Anurag Relan, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mrs. Mireille Sanders
Mrs. Mireille Sanders
Chief Operations Officer
Chief Operations Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Jeroen Wakkerman
Mr. Jeroen Wakkerman
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Fabrice Chouraqui
Mr. Fabrice Chouraqui
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Stephen Toor
Mr. Stephen Toor
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Alexander Breidenbach
Dr. Alexander Breidenbach
Chief Business Officer
Chief Business Officer
--
--
Ms. Ines Bernal
Ms. Ines Bernal
Chief People Officer
Chief People Officer
--
--
Mr. Steven Baert
Mr. Steven Baert
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, May 14
Updated: Wed, May 14
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Silverberg Bernstein Capital Management, LLC
0.08%
Other
99.92%
Shareholders
Shareholders
Proportion
Silverberg Bernstein Capital Management, LLC
0.08%
Other
99.92%
Shareholder Types
Shareholders
Proportion
Investment Advisor
0.08%
Other
99.92%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
10
57.25K
0.08%
-7.99K
2025Q1
11
75.56K
0.11%
-12.14K
2024Q4
11
75.65K
0.11%
-65.36K
2024Q3
11
69.30K
0.10%
-54.56K
2024Q2
9
52.15K
0.08%
-64.69K
2024Q1
9
45.12K
0.07%
-72.64K
2023Q4
9
45.06K
0.07%
-55.56K
2023Q3
9
38.77K
0.06%
-67.63K
2023Q2
10
27.05K
0.04%
-248.66K
2023Q1
10
87.93K
0.13%
-131.45K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Silverberg Bernstein Capital Management, LLC
48.00K
0.07%
--
--
Mar 31, 2025
Morgan Stanley Smith Barney LLC
2.50K
0%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
2.09K
0%
--
--
May 31, 2025
Morgan Stanley & Co. LLC
400.00
0%
+300.00
+300.00%
Mar 31, 2025
Coldstream Capital Management, Inc.
106.00
0%
+106.00
--
Mar 31, 2025
Osaic Holdings, Inc.
--
0%
-483.00
-100.00%
Mar 31, 2025
Farther Finance Advisors, LLC
--
0%
-11.00
-100.00%
Mar 31, 2025
UBS Financial Services, Inc.
--
0%
-10.00
-100.00%
Mar 31, 2025
Orion Portfolio Solutions, LLC
--
0%
-11.71K
-100.00%
Dec 31, 2023
Aperio Group, LLC
--
0%
-326.00
-100.00%
Dec 31, 2024
Related ETFs
Name
Proportion
No Data
Dividend
A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
KeyAI